Skip to main content
OpenTrials
Completed

NCT Number: NCT02073669

Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults

The aim of study is to evaluate the prevalence of latent TB in second generation immigrants from countries with high incidence of tuberculosis (above 20 of 100,000) compare to the control native Israelis without a family member who was born in a country with high incidence of tuberculosis. Using study questionnaire IGRA and tuberculin skin test the investigators expect that the second generation immigrants group will have more positive IGRA test than the control native group.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Latent Tuberculosis Actinomycetales Infections Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Latent Infection Mycobacterium Infections Tuberculosis

Age range

18 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Israeli Defense Forces, Ramat Gan, Israel

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-25
  • Men and women
  • Second generation immigrants from countries with high incidence of tuberculosis (above 20 of 100,000).
  • Native Israelis without a family member who was born in a country with high incidence of tuberculosis.

Exclusion criteria

  • Prior contact with a tuberculosis patient
  • Working (more than a month) in high risk setting such as health care workers, working with immigrants from countries with high incidence of tuberculosis.
  • HIV infection and any immunodeficiency condition.
  • Recent live-virus vaccination
  • Acute infectious disease
  • Prior serious reaction to tuberculin skin test
  • Pregnancy

Treatment and study plan

Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)

Procedure

Primary outcomes

  1. Interferon gamma release assay ( IGRA)

    Time frame: Up to 3 months after tuberculin skin test

Sponsors and collaborators

Lead sponsor

Sheba Medical Center

Other Gov

Collaborators

  • Tel Aviv Lung Association

Registry information

Official study title

Better Identification of Latent Tuberculosis Infection Among Israeli Young Adults by Comparison Skin Tests and Interferon Gamma Releasing Assays (IGRA)

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Feb 27, 2014
Registry last updated
Jan 25, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.